Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 2 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2

Conditions

Hot Flashes 5Breast Neoplasms 4Prostatic Neoplasms 2Head and Neck Neoplasms 2Depression 2Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 1Sleep Wake Disorders 1Lymphoma, Follicular 1Depressive Disorder, Major 1Depressive Disorder 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1Bipolar Disorder 1

Interventions

Cisplatin 141Radiotherapy 115Cetuximab 95Docetaxel 69Radiotherapy, Intensity-Modulated 55Carboplatin 47pembrolizumab 46Surveys and Questionnaires 46Paclitaxel 41Fluorouracil 39Radiation 29Blood Specimen Collection 27Drug Therapy 26Erlotinib Hydrochloride 23Nivolumab 21Surgical Procedures, Operative 17Standard of Care 16Magnetic Resonance Spectroscopy 16Radiosurgery 14Pemetrexed 14Gemcitabine 14Everolimus 13Celecoxib 13durvalumab 12Low-Level Light Therapy 12Immunohistochemistry 12Cyclophosphamide 12Capecitabine 12Amifostine 12Chemoradiotherapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Head and Neck Neoplasms × Venlafaxine Hydrochloride × Clear all
NCT04977271 2025-02-04

Mood Disorders in Head and Neck Cancer Patients

University of Alabama at Birmingham

Phase 4 Withdrawn
Head & Neck

Depressive Disorder, Head and Neck Neoplasms

NCT05724849 2024-01-18

Venlafaxine for the Prevention of Depression in Patients With Head and Neck Cancer

Vanderbilt University Medical Center

Phase 2 Withdrawn
Head & Neck

Depression, Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡